肝炎表面抗原,乙型

肝炎表面抗原,乙型的相关文献在1998年到2021年内共计497篇,主要集中在内科学、临床医学、基础医学 等领域,其中期刊论文497篇、专利文献230599篇;相关期刊101种,包括国际生物制品学杂志、中华实验和临床病毒学杂志、国际检验医学杂志等; 肝炎表面抗原,乙型的相关文献由1937位作者贡献,包括成军、毕胜利、陈新月等。

肝炎表面抗原,乙型—发文量

期刊论文>

论文:497 占比:0.22%

专利文献>

论文:230599 占比:99.78%

总计:231096篇

肝炎表面抗原,乙型—发文趋势图

肝炎表面抗原,乙型

-研究学者

  • 成军
  • 毕胜利
  • 陈新月
  • 任红
  • 宋淑静
  • 李明慧
  • 杨东亮
  • 谭昌耀
  • 贾志远
  • 高志良
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 王子豪; 于沛伶; 潘玉成; 李运清; 刘昂; 薛庆节
    • 摘要: 目的 构建人IL-2与HBsAg融合基因并转化到BCG中构建重组BCG(recombinant BCG,rBCG),为制备治疗和预防乙型肝炎和结核病的二联疫苗奠定基础.方法 以IL-2 pMalLP质粒和HBsAg pMalLP质粒为模板,设计引物,利用PCR技术扩增HBsAg和IL-2基因,进行重叠PCR获得融合基因IL-2-HBsAg并纯化,将融合基因克隆至穿梭表达载体pMV261得到重组质粒,电转化导入BCG感受态细胞,以蛋白质印迹法检测融合基因在rBCG中的表达.结果 PCR扩增得到JL-2和HBsAg,通过重叠PCR获得IL-2-HBsAg融合基因后成功插入穿梭表达载体,rBCG能表达融合蛋白.结论 构建人IL-2与HBsAg融合基因重组质粒并导人BCG,获得了稳定表达融合蛋白的rBCG.
    • 马娟; 唐仕芳; 刘慧敏; 张娅琴; 邓义娟; 汪丽; 李力
    • 摘要: 乙型肝炎病毒(HBV)母婴传播是导致我国人群慢性乙型肝炎(CHB)发病的主要原因,预防HBV母婴传播是控制CHB的关键.在《乙型肝炎病毒母婴传播预防临床指南(2013)》[以下简称为《HBV预防指南(2013)》]基础上,根据最新循证医学证据和文献报道,对其进行进一步修订和更新,颁布《乙型肝炎病毒母婴传播预防临床指南(2020)》[以下简称为《HBV预防指南(2020)》],从而使我国HBV母婴传播预防管理策略得到进一步优化.《HBV预防指南(2020)》更新推荐建议主要包括以下9个方面.①HBV感染临床诊断标准更新要点;②HBV母婴传播更新要点;③CHB妇女妊娠时机选择更新要点;④CHB孕妇孕期管理更新要点;⑤HBV母婴传播的新生儿免疫预防更新要点;⑥产妇乙型肝炎表面抗原(HbsAg)呈阴性,而家庭其他成员HBsAg呈阳性的子代HBV传播预防;⑦鼓励CHB产妇对其新生儿进行母乳喂养新增要点;⑧对CHB孕妇分娩婴幼儿随访更新要点;⑨预防HBV母婴传播的其他推荐建议更新要点.笔者拟就《HBV预防指南(2020)》的上述9个方面新增、更新要点,并结合其相关临床研究最新进展,对该指南进行解读,旨在帮助产科及儿科医师更新这方面知识,为临床更好预防HBV母婴传播提供参考.
    • 丁丞; 黄晨阳; 陈灿; 周雨晴; 严丹莹; 刘晓晓; 傅晓芳; 蓝蕾; 杨仕贵
    • 摘要: 目的 分析传染病示范区基层医疗机构HBV血清学标志物检测的准确性,为准确评估示范区乙型肝炎流行水平提供参考.方法 在全国6个乙型肝炎示范区内,定额抽取乙型肝炎普通人群观察队列并采集相应的血标本,由基层医疗机构进行检测HBsAg和抗-HBs,同时送第三方平台进行检测,分析两组检测结果的差异性和一致性.采用SAS 9.4软件对数据进行分析.结果 HBsAg指标检测5756份,抗-HBs指标检测5263份.基层医疗机构HBsAg和抗-HBs指标的检测结果与第三方平台检测结果对比,HBsAg指标符合率为97.13%,抗-HBs指标符合率为77.33%.HBsAg和抗-HBs指标的Kappa值分别为0.56(95% CI0.50~0.62)和0.54(95% CI 0.52~0.56),McNemar检验提示差异均具有统计学意义(P值均<0.01).各示范区检测结果与第三方结果比较,差异具有统计学意义(P <0.05或<0.01),江苏和广东示范区HBsAg指标一致率较高(Kappa值分别为0.87和0.81),甘肃和广东示范区抗-HBs指标一致率较高(Kappa值均为0.74).以第三方平台检测结果作为参照,基层医疗机构检测HBsAg的敏感度为40.51%,特异度为99.96%;抗-HBs的敏感度为73.18%,特异度为84.31%.广东和江苏示范区HBsAg指标鉴别能力较高(约登指数分别为0.69和0.80),甘肃和广东示范区抗-HBs指标鉴别能力较高(约登指数分别为0.78和0.76).结论 乙型肝炎示范区基层医疗机构HBV血清学标志物检测结果与第三平台检测结果之间存在一定差异.基层医疗机构当前的检测手段适用于排除HBV感染者,检测实施过程中假阴性的情况需要加以关注.
    • 郑小华; 赵鹏伟; 贾海琴
    • 摘要: Objective To investigate the relationship between HBV -DNA load and serum markers in chronic hepatitis B( CHB) patients in Hohhot,Inner Mongolia,and to explore the mutation of HBV genotype and nucleoside analogue.Methods From January 2015 to December 2017,one hundred and ninety-three CHB patients hospitalized in the People's Hospital of Inner Mongolia were selected randomly.The clinical diagnostic criteria for all admitted patients were based on the " Guidelines for the Prevention and Treatment of Chronic Hepatitis B" jointly formulated by the Infectious Diseases Society of 2010. The HBV -DNA load of HBV was detected by real -time quantitative PCR,and the correlation between HBV -DNA load and serum markers was analyzed. Seventy -nine patients were selected from 193 hospitalized patients,PCR-reverse dot blot hybridization was used to analyze HBV genotyping and the drug resistance mutations of different genotypes.Results The differences of HBeAb level and HBV-DNA load between HBeAg positive patients and negative patients were statistically significant(all P<0.001). Of 79 serum specimens of HBV infected people,9 cases(11.4% ) were B genotypes,and 70 cases of C genotype (88.6% ).Of them,25 cases had different loci variation,the rate of variation was 31.6% (25/79),with the unit point rtS213T mutation dominated,accounting for about 24.0% (6/25).Conclusion In Hohhot Inner Mongolia patients with CHB,HBV-DNA load with HBeAg and HBe Ab level are correlated;genotype in patients including B type and C type,which is mainly genotype C;patients with CHB mainly had drug resistance to lamivudine and adefovir dipivoxil, mutations including rtS213T,and hybrid mutation.%目的 探讨内蒙古自治区呼和浩特地区慢性乙型肝炎患者病毒脱氧核糖核酸( HBV-DNA)载量与血清标志物水平间的关系,基因分型与核苷(酸)类似物耐药突变情况.方法 选取内蒙古自治区人民医院2015年1月至2017年12月确诊的慢性乙型肝炎患者193例为研究对象,采用实时荧光定量聚合酶链式反应(PCR)法检测HBV-DNA载量,分析其与血清学标志物的相关性.并从193例患者中选取79例采用PCR-反向点杂交法检测HBV基因分型和耐药突变,分析不同基因型患者的耐药突变情况.结果 e抗原阳性和阴性患者的e抗体水平与HBV-DNA载量比较差异均有统计学意义(均P<0.001). 79例HBV感染者中,B基因型9例(11.4% ),C基因型70 例(88.6% ).其中有25 例发生不同位点变异,变异率为31.6% (25/79),以单位点rtS213T突变为主,约占24.0% (6/25).结论 呼和浩特地区慢性乙型肝炎患者的HBV-DNA载量与e抗原、e抗体水平相关;基因型主要为B和C型,以C基因型为多;慢性乙型肝炎患者主要对拉米夫定、阿德福韦酯耐药,突变以rtS213T为主,也有混合位点的突变.
    • 徐国萍; 李倩; 戴玉柱; 李青; 周华君; 成军
    • 摘要: 目的 探讨乙型肝炎病毒(hepatitis B virus, HBV)感染者持续低水平表达乙型肝炎表面抗原(hepatitis B surface antigen, HBsAg)的S基因序列特征.方法 收集2016年2月至2017年12月解放军第九〇三医院和杭州市江干区人民医院的非活动性HBsAg 携带者1 308 例的血清样本,根据HBsAg血清表达水平分为高水平组(≥10 IU/mL)和低水平组(<10 IU/mL).对低水平组患者进行HBV S基因测序,另外在低水平组年龄和血清学模式( HBeAg阴性)相匹配的基础上,在高水平组患者中随机选择(分层抽样)100例进行HBV S基因测序,并对低水平HBsAg组患者的HBV S基因序列和高水平HBsAg组患者的HBV参考S基因序列进行比较分析.数据为正态分布的结果以均数±标准差表示,采用t检验;非正态分布的结果以M(QR)表示,采用Mann-Whitney U检验;卡方检验或Fisher精确检验比较两组间的连续变量和分类变量.结果 低水平组血清标本276份;高水平组血清标本1 032份,其中HBsAg、HBeAg、抗-HBc阳性257份,HBsAg、抗-HBe和抗-HBc阳性753份,HBsAg和抗-HBc阳性22份.对276例低水平组中126例感染者进行了成功的HBV S基因测序,根据低水平组年龄情况,选取高水平组内HBeAg阴性的随机标本100例,对其中94例感染者进行了基因分型和血清分型.结果显示,高水平组(94例)和低水平组(126例)在HBV血清学标志物、HBV DNA水平和HBV基因型分布差异均有统计学意义(均P<0.05).建立的非活动性HBeAg携带者中B型和C型的参考序列与上海市、成都市、武汉市、云南省、北京市报道的B和C基因型序列具有很高的同源性(99.6%~100.0%),与日本、韩国的NCBI基因型B和C参考序列具有很高的同源性(98.2%~99.6%),但与一些远离中国地区患者具有较低的同源性(加拿大和印度尼西亚分别为98.2%和98.7%).低水平组B基因型小蛋白(即主要蛋白,SHB)的氨基酸突变数为71,热点突变数为19,均高于高水平组的39和8,比较差异均有统计学意义(χ2 值分别为12.303 和4.766,均P<0.05).低水平组的氨基酸突变位点分布在主要亲水区(major hydrophilic region , MHR)的两侧(氨基酸残基40-49和198-220). C基因型两组间氨基酸突变数和热点突变数差异均无统计学意义(χ2 值分别为0.383和0.409,均P>0.05).在B基因型中,低水平组有12个单位点突变,4个双位点共突变,其中1个单位点突变(S210R)和3个双位点共突变(G44E/V+T45P/I、G44E/V+L49P/R、N40S+I208T)不是热点突变;高水平组有2个单位点突变和2个双位点共突变,两组突变频率差异有统计学意义(χ2 =7.533,P=0.006).在C基因型中,低水平组有5个单位点突变(T5A、A45T、T47A/K、Q101R、I126S/T),高水平组有1个单位点突变(N3S),两组突变频率差异有统计学意义(χ2 =47.914,P=0.000).结论 MHR两侧多个区域和多个位点的显著突变(包括共突变)可能是导致非活动性HBsAg携带者HBsAg表达水平低的原因之一.%Objective To reveal the characteristics of S gene sequence of hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-infected patients with low HBsAg level.Methods From February 2016 to December 2017, 1 308 serum samples of inactive HBsAg carriers were collected from the 903rd Hospital of PLA and Hangzhou Jianggan District People′s Hospital.The cases were divided into high-level group and low-level group according to the level of serum HBsAg (10 IU/mL) expression.The HBV S gene was sequenced in patients with low-level HBsAg expression.In addition, in patients with high-level HBsAg, 100 patients were randomly selected (stratified sampling) for HBV S gene sequencing based on the matching of age and serological pattern (hepatitis B e antigen [HBeAg] negative) of low-level HBsAg group.A comparative analysis was conducted between HBV S gene sequences from inactive HBsAg carrier in low HBsAg expression group and the HBV reference S gene sequences from inactive HBsAg carrier in high HBsAg expression group .The results of normal distribution data were expressed as Mean ±SD, and analyzed using t-test.The results of non-normal distribution data were expressed by M(QR), and analyzed using Mann-Whitney U test.Chi-square test or Fisher exact test was used to compare continuous variables and classification variables between the two groups .Results There were 276 serum samples from the low level group and 1 032 serum samples from the high level group , including 257 HBsAg/HBeAg/anti-HBc-positive cases, 753 HBsAg/anti-HBe/anti-HBc-positive cases, and 22 HBsAg/anti-HBc-positive cases.Successful HBV S gene sequencing was performed on 126 out of 276 patients in the low-level HBsAg group.According to the age inthe low-level HBsAg group, 100 samples with negative HBeAg in the high-level HBsAg group were randomly selected , among which 94 patients were genotyped and hemotyped.The results showed that there were statistically significant differences in HBV serological markers , HBV DNA level and HBV genotype distribution between the high level group (94 cases) and the low level group (126 cases) (all P<0.05).The ASC-R-B and ASC-R-C genotypes reported in this study had high homology (99.6%-100.0%) with those reported in Shanghai , Chengdu, Wuhan, Yunnan and Beijing of China , and high homology (98.2%-99.6%) with those reported in Japan and Korea of NCBI genotype B and C reference sequences, but had low homology with patients far away from China (98.2% in Canada and 98.7% in Indonesia).In genotype B of the low level group , the amino acid mutation number of SHB protein was 71, and the hot spot mutation number was 19, both higher than those in the high level group (39 and 8, respectively). The difference was statistically significant (χ2 =12.303 and 4.766, respectively, both P<0.05).Amino acid mutation sites in the low HBsAg group were mainly distributed on both sides of the major hydrophilic region (MHR) (amino acid residues 40 -49 and 198 -220).There were no significant differences in amino acid mutation number and hot spot mutation number between the two groups of C genotype (χ2 =0.383 and 0.409, respectively, both P>0.05).For genotype B, 12 single point mutations and 4 dual co-mutations were found in low level group.Among them, one single point mutation (S210R) and 3 dual co-mutations (G44E/V+T45P/I, G44E/V+L49P/R and N40S+I208T) were not hot spot mutations , while 2 dual co-mutations and 2 single point mutations were found in high level group.The difference between two groups was statistical significant (χ2 =7.533,P =0.006).For genotype C, 5 single point mutations ( T5A, A45T, T47A/K, Q101R and I126S/T) were found in low level group and 1 single point mutation (N3S) in high level group.The difference in mutation frequency between two groups were statistical significant (χ2 =47.914,P=0.000).Conclusions Significant mutations in multiple regions and at multiple sites ( including co-mutations) on both sides of the MHR may be one of the causes of low HBsAg expression level in this population .
    • 杨永刚; 滕勇; 李新征; 汪隆娟; 沈琳; 朱伊钒; 王冬辉
    • 摘要: Objective To discover the performance differences between two colloidal gold test strips for HBsAg and to explore their clinical applicability.Methods The bias and imprecision of A and B HBsAg kits were analyzed,and the C50,C5-C95 intervals and imprecision curves were compared.At the same time,8 423 specimens collected in the Third People's Hospital of Hangzhou from January to December 2017 were determined for HBsAg by these colloidal gold kits and the so-called "gold standard method"-chemiluminescence assay.The performance differences between the two colloidal gold kits were compared and the consistency analysis was carried out.Results The concentrations of C48 for kit A (2.95 IU/mL) was lower than C50 for kit B (7.08 IU/mL),and had better sensitivity.The C0-C100value of kit A was 0.80-8.85 IU/mL,and was narrower than that of kit B (2.01-16.09 IU/mL).The consistency of kit B (Kappa=0.949) was superior to kit A (Kappa=0.834) when compared with chemiluminescence assay,as well as positive predictive values (93.68 % vs 74.56 %).Conclusions The kit A has better sensitivity and detection range,but kit B has more superiorities than kit A in emergency preliminary screening and preoperative detection.%目的 探讨两种HBsAg胶体金试纸条性能上的差异,及其在临床上的适用性.方法 对A、B两种检测试剂做偏倚和不精密度分析,比较两种试剂的C50、C5~C95区间以及不精密度曲线;同时用杭州市第三人民医院2017年1-12月术前急查HBsAg的共8 423份样本,以免疫化学发光法检测的结果为“金标准”,比较两种胶体金试剂之间的性能差异,并进行一致性分析.结果 A试剂的C48浓度为2.95 IU/mL,低于B试剂的C50浓度(7.08 IU/mL),具有较好的灵敏度.A试剂的C0~C100值为0.80~8.85 IU/mL,B试剂为2.01~16.09 IU/mL,A试剂的不精密度比B试剂窄.B试剂与化学发光法的一致性(Kappa=0.949)优于A试剂(Kappa=0.834),同时B试剂的阳性预测值为93.68%,高于A试剂的74.56%.结论 A试剂虽然具有较好的灵敏度和检测范围,但B试剂应用于急诊初步筛查和手术前检测方面比A试剂更具有优势.
    • 张欣; 闫玲; 卢颖; 卫凯平; 刘秩秀; 肖义炜; 丁锋; 庄辉; 李杰
    • 摘要: 目的 分析e抗原(HBeAg)阳性的慢性乙型肝炎病毒(HBV)感染且未经抗病毒治疗的孕妇血清HBV DNA水平与HBV表面抗原(HBsAg)滴度的相关性,并探讨PreS/S区基因突变对二者相关性的影响.方法 将882例HBsAg、HBeAg和HBV DNA均阳性且未经抗病毒治疗的慢性HBV感染孕妇临产前血清样本纳入分析.分别采用雅培i2000和m2000系统定性或定量检测HBsAg、HBeAg和HBV DNA水平.采用型特异性引物巢氏聚合酶链反应(nPCR)法进行HBV基因分型.另外,匹配HBV DNA水平与HBsAg滴度具有相关性和HBV DNA水平较HBsAg滴度偏高的孕妇血清样本,用nPCR方法进行PreS/S区扩增,对PCR产物直接测序后采用MEGA6.0软件分析突变位点.计量资料采用Mann-WhitneyU检验,计数资料采用x2检验,相关性分析采用Spearman等级相关性分析.结果 HBeAg阳性慢性HBV感染孕妇血清HBsAg滴度与HBV DNA水平呈正相关(r=0.754,P<0.01);与对照组相比,HBV PreS区A60V(100%与15.38%,x2=7.61,P<0.01)、V90A(100%与30.77%,x2=4.43,P<0.05)和I161T位点(80.00%与0,x 2=9.14,P<0.01)突变时HBsAg滴度明显降低.结论 HBeAg阳性慢性HBV感染孕妇,血清HBV DNA水平与HBsAg滴度呈正相关,HBsAg滴度可作为HBV DNA水平的替代指标.PreS/S区A60V、V90A和I161T氨基酸位点单独或联合突变可能是导致HBsAg滴度显著下降进而影响其与HBV DNA水平相关性的原因之一.%Objective To analyze the correlation between serum HBV DNA level and HBsAg titer in hepatitis B e antigen positive pregnant women without antiviral therapy,and investigate the impact of genomic variability of preS/S regions on their correlations.Methods Prenatal serum samples from 882 pregnant women with chronic HBV infection who were positive for HBsAg,HBeAg and HBV DNA and were not on antiviral therapy were included in the analysis.The Abbott i2000 and m2000 systems were used to qualitatively or quantitatively detect HBsAg,HBeAg and HBV DNA levels,respectively.HBV genotyping was performed using a type-specific primer nested polymerase chain reaction (nPCR).In addition,serum samples of pregnant women with HBV DNA levels correlated with HBsAg titer and HBV DNA levels higher than HBsAg titers were used to perform preS/S region amplification by nPCR method.PCR products were directly sequenced and mutation sites were analyzed by MEGA6.0 stasticial software.Mann-Whitney U test was used for the measurement data,and 2-test test for count data.Correlations between variables were analyzed using Spearman's rank correlation.Results Serum HBsAg titer of HBeAg-positive pregnant women was positively correlated with HBV DNA level (r =0.754,P < 0.01).Compared with the control group,mutation sites A60V (100% vs.15.38%,x2 =7.61,P < 0.01),V90A (100% vs.30.77%,x 2 =4.43,P < 0.05) and I161T ofHBV preS/S region (80.00% vs.0,2x 2 =9.14,P < 0.01) showed a significant decrease in HBsAg titer.Conclusion Serum HBV DNA levels were positively correlated with HBsAg titer in HBeAg-positive pregnant women.Therefore,serum HBsAg titer may be used as a surrogate marker of serum HBV DNA.Single or multiple amino acid mutations sites A60V,V90A,and I161T in preS/S region may be one of the reasons that lead to a significant drop in HBsAg titer and affect its correlation with-HBV DNA levels.
    • 刘立; 刘春云; 李俊义; 王霖; 李卫昆; 李惠敏; 常丽仙; 王辉
    • 摘要: 目的 分析低水平乙型肝炎表面抗原(HBsAg)患者肝脏组织病理的变化,为低水平 HBsAg患者的病情判断提供依据.方法 选取63例HBsAg水平者作为研究对象.对该类患者进行肝组织病理学检查,并检测其相关指标水平;分析病理炎症分级和纤维化分期.结果 63例研究者中G01例、G123例、G237例、G32例、G40例,S01例、S135例、S221例、S36例、S40例.肝组织炎症分级与球蛋白有相关性(H=7.441,P=0.05),而其他因素无关(P>0.05).肝组织纤维化分期与天门冬氨酸氨基转移酶、血小板有相关性(P0.05).结论 低水平 HBsAg患者中有相当比例的患者炎症分级不低于G2和(或)纤维化分期不低于S2,具备抗病毒的指征.其炎症分级与球蛋白水平密切相关,纤维化分期与天门冬氨酸氨基转移酶、血小板密切相关.
    • 高胜利; 钮志林; 赵刚; 徐密琴; 沈燕; 俞净; 叶杨; 何丽华; 金文娟; 孙桂英
    • 摘要: Objective To investigate the efficacy and safety of interferon-α (IFN-αt) given additionally or sequentially after effective inhibition of HBV DNA by long-term entecavir (ETV) therapy versus ETV alone in the treatment of chronic hepatitis B (CHB).Methods A total of 27 CHB patients with negative HBV DNA who were admitted to department of infectious diseases in Wujiang Hospital Affiliated to Nantong University from January 2013 to December 2015 had been treated with ETV antiviral therapy for 3 or more years and had no contraindications for IFN-α therapy were enrolled and randomly divided into three groups,with 9 patients in each group.The patients in the control group were given ETV alone,those in sequential group were given IFN-α sequentially after ETV therapy,and those in the combination group were given IFN-α additionally after ETV therapy.Serum HBV DNA,HBV serum markers,routine blood test,and liver function were measured at 0,12,24,36,and 48 weeks of treatment.The patients' treatment outcomes were observed and a statistical analysis was performed.A one-way analysis of variance was used for comparison between multiple groups,and the Scheffe test was used for further comparison between two groups.Results There were not drop-outs,and no patient experienced serious adverse reactions.One patient in the sequential group experienced viral rebound after 24 weeks of treatment without any clinical symptoms and had normal liver function parameters.At the end of treatment,the sequential group and the combination group had a significantly higher absolute value of the reduction in HBsAg than the control group (both P < 0.001).Two patients each in the sequential group and the combination group achieved HBsAg clearance,resulting in a clearance rate of 22%.No patient in the control group achieved HBsAg clearance.Conclusion IFN-α given additionally or sequentially after effective inhibition by ETV is safe and may achieve a significantly greater reduction in HBsAg than ETV alone.A few patients even achieve clinical cure.%目的 探讨经恩替卡韦(ETV)长期治疗,有效抑制HBV DNA后,采取序贯或联合IFNα治疗与单用ETV治疗的疗效与安全性比较.方法 收集2013年1月-2015年12月南通大学附属吴江医院门诊和住院的慢性乙型肝炎患者27例,所有患者已经ETV抗病毒治疗3年或以上,HBV DNA阴性,无IFN治疗禁忌证,将纳入患者随机分为3组,每组9例.对照组:继续ETV治疗;序贯组:更换为IFNα序贯治疗;联合组:联合IFNα治疗.检测治疗0、12、24、36、48周时血清HBV DNA、HBV血清标志物、血常规、肝功能,观察治疗情况,记录结果并进行统计分析.计量资料多组间比较采用单因素方差分析,进一步两两比较采用Scheffe检验.结果 无退出研究病例,无严重不良事件发生;序贯组有1例24周后出现了病毒反弹,但无临床症状,肝功能各项生化指标正常.治疗结束时,序贯组和联合组HBsAg下降的绝对值均显著高于对照组(P值均<0.001);序贯组和联合组各有2例出现了HBsAg的阴转,阴转率22%;对照组未出现HBsAg的阴转病例.结论 ETV有效抑制病毒复制后的IFNα序贯或联合治疗可能是安全的,HBsAg下降水平优于ETV单药治疗,少数患者出现临床治愈.
    • 曹振环; 鲁俊锋; 武亚丽; 郑燕红; 陈新月
    • 摘要: Objective To investigate the association between HBsAg clearance and serum level of granulocyte-macrophage colony stimulating factor (GM-CSF) in inactive HBsAg carriers receiving pegylated interferon (PEG-IFN) alpha-2a.Methods A total of 20 inactive HBsAg carriers who visited Beijing YouAn Hospital,Capital Medical University,from January 2013 to January 2016 were enrolled,and after 24 weeks of PEG-IFN alpha-2a treatment,13 achieved HBsAg clearance (R group) and 7 did not achieve HBsAg clearance (NR group).The Lurninex technique was used to measure the serum level of GM-CSF at baseline and at weeks 12 and 24 of treatment.The serum level of GM-CSF was also measured for 11 healthy controls (HC group).The t-test or an analysis of variance was used for comparison of continuous data between groups,and the Bonferroni test was used for further comparison between two groups.The chi-square test was used for comparison of categorical data between groups.Results The R and NR groups had a significantly higher serum GM-CSF level than the HC group (42.63 ±11.24 pg/ml and 46.77 ± 10.52 pg/ml vs 11.97 ± 3.85 pg/ml),and there was a significant difference between the three groups (F =4.482,P =0.02).At weeks 12 and 24 of PEG-IFNα-2a treatment,the R group had a significantly higher serum GM-CSF level than the NR group (t =22.422 and 17.782,both P <0.05).In the R group,the serum GM-CSF level was 42.63 ± 11.25 pg/ml at baseline,significantly increased to 83.31 ± 14.20 pg/ral at week 12 of treatment,and then significantly decreased to 32.34 ±8.06 pg/ml at week 24 of treatment (F=7.655,P =0.002).In the NR group,the serum GM-CSF level was 46.77 ± 10.52 pg/ml at baseline and significantly decreased to 25.90 ± 7.06 pg/ml at week 12 of treatment and 9.43 ± 2.45 pg/ml at week 24 of treatment (F =5.264,P =0.016).Conclusion In inactive HBsAg carriers receiving PEG-IFN alpha-2a treatment,the increase in serum GM-CSF level may indicate HBsAg clearance.%目的 探讨聚乙二醇干扰素(PEG-IFN)α-2a治疗非活动性HBsAg携带者(IHC)发生HBsAg清除与血清粒-巨噬细胞集落刺激因子(GM-CSF)水平的关系.方法 收集2013年1月-2016年1月就诊于首都医科大学附属北京佑安医院门诊的IHC患者20例,经PEG-IFNα-2a治疗24周后13例获得HBsAg清除(R组),7例未获得HBsAg清除(NR组).用Luminex技术检测患者基线、治疗12周和治疗24周血清GM-CSF水平.同时检测11例健康人(HC组)血清GM-CSF水平.计量资料2组间比较采用t检验,多组间比较采用方差分析,进一步两两比较采用Bonferroni检验.计数资料组间比较采用x2检验.结果 R组、NR组及HC组基线血清GM-CSF水平分别为(42.63±11.24)pg/ml、(46.77±10.52) pg/ml(11.97±3.85) pg/ml,3组之间比较差异具有统计学意义(F=4.482,P=0.02),R组与NR组GM-CSF水平均明显高于HC组(P值均<0.05).PEG-IFNα-2a治疗后12周和24周,R组血清GM-CSF水平均明显高于NR组[(83.31±14.20) pg/ml vs(25.90±7.06) pg/ml,t=22.422,P<0.001;(32.34±8.06) pg/ml vs(9.43±2.45) pg/ml,t=17.782,P=0.001].R组患者基线抗病毒治疗12周、24周时,血清GM-CSF水平呈现先升高后下降趋势,3个时间点比较,差异有统计学意义(F=7.655,P=0.002).NR组患者基线抗病毒治疗12周、24周时,血清GM-CSF水平呈明显下降趋势,3个时间点比较,差异有统计学意义(F=5.264,P=0.016).结论 PEG-IFNα-2a治疗IHC过程中血清GM-CSF水平升高可能预示着HBsAg清除.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号